Article
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
AIDS (London, England) - 27 Mar 2010
Peeters Monika, Vingerhoets Johan, Tambuyzer Lotke, Azijn Hilde, Hill Andrew, De Meyer Sandra, Picchio Gaston
Abstract excerpt
Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the pha...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.